ADMA Biologics Inc
NASDAQ:ADMA

Watchlist Manager
ADMA Biologics Inc Logo
ADMA Biologics Inc
NASDAQ:ADMA
Watchlist
Price: 19.28 USD -1.33% Market Closed
Market Cap: 4.6B USD

Intrinsic Value

The intrinsic value of one ADMA stock under the Base Case scenario is 17.46 USD. Compared to the current market price of 19.28 USD, ADMA Biologics Inc is Overvalued by 9%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ADMA Intrinsic Value
17.46 USD
Overvaluation 9%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
ADMA Biologics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about ADMA?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ADMA valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for ADMA Biologics Inc.

Explain Valuation
Compare ADMA to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ADMA?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ADMA Biologics Inc

Current Assets 402.7m
Cash & Short-Term Investments 61.4m
Receivables 137.7m
Other Current Assets 203.6m
Non-Current Assets 166m
PP&E 78.8m
Intangibles 4m
Other Non-Current Assets 83.2m
Current Liabilities 56.5m
Accounts Payable 24m
Accrued Liabilities 24.8m
Other Current Liabilities 7.7m
Non-Current Liabilities 81m
Long-Term Debt 70.1m
Other Non-Current Liabilities 10.9m
Efficiency

Free Cash Flow Analysis
ADMA Biologics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
ADMA Biologics Inc

Revenue
488.6m USD
Cost of Revenue
-221.3m USD
Gross Profit
267.3m USD
Operating Expenses
-100.3m USD
Operating Income
167m USD
Other Expenses
42.4m USD
Net Income
209.4m USD
Fundamental Scores

ADMA Profitability Score
Profitability Due Diligence

ADMA Biologics Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

72/100
Profitability
Score

ADMA Biologics Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

ADMA Solvency Score
Solvency Due Diligence

ADMA Biologics Inc's solvency score is 86/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
High Interest Coverage
86/100
Solvency
Score

ADMA Biologics Inc's solvency score is 86/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ADMA Price Targets Summary
ADMA Biologics Inc

Wall Street analysts forecast ADMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADMA is 26.18 USD with a low forecast of 17.17 USD and a high forecast of 31.5 USD.

Lowest
Price Target
17.17 USD
11% Downside
Average
Price Target
26.18 USD
36% Upside
Highest
Price Target
31.5 USD
63% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

ADMA Biologics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ADMA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ADMA Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ADMA stock?

The intrinsic value of one ADMA stock under the Base Case scenario is 17.46 USD.

Is ADMA stock undervalued or overvalued?

Compared to the current market price of 19.28 USD, ADMA Biologics Inc is Overvalued by 9%.

Back to Top